The estimated Net Worth of Sudhir Agrawal is at least $123 Thousand dollars as of 22 December 2008. Dr Agrawal owns over 8,585 units of Idera Pharmaceuticals stock worth over $57,144 and over the last 17 years he sold IDRA stock worth over $65,589.
Dr has made over 3 trades of the Idera Pharmaceuticals stock since 2008, according to the Form 4 filled with the SEC. Most recently he sold 8,585 units of IDRA stock worth $65,589 on 22 December 2008.
The largest trade he's ever made was exercising 82,553 units of Idera Pharmaceuticals stock on 7 July 2008 worth over $330,212. On average, Dr trades about 6,679 units every 8 days since 2008. As of 22 December 2008 he still owns at least 132,892 units of Idera Pharmaceuticals stock.
You can see the complete history of Dr Agrawal stock trades at the bottom of the page.
Dr. Sudhir Agrawal is the Scientific Advisor at Idera Pharmaceuticals.
Dr Agrawal is 66, he's been the Scientific Advisor of Idera Pharmaceuticals since . There are 1 older and 15 younger executives at Idera Pharmaceuticals. The oldest executive at Idera Pharmaceuticals, Inc. is Dr. Sudhir Agrawal D.Phil., DPHIL, F.R.S.C., 67, who is the Scientific Advisor.
Sudhir's mailing address filed with the SEC is C/O IDERA PHARMACEUTICALS, INC., 167 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 17 years, insiders at Idera Pharmaceuticals have traded over $20,746,904 worth of Idera Pharmaceuticals stock and bought 38,459,430 units worth $53,771,070 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp Baker Bro..., and Invest Corp Pillar Pharmace.... On average, Idera Pharmaceuticals executives and independent directors trade stock every 43 days with the average trade being worth of $309,429. The most recent stock trade was executed by John J. Kirby on 17 December 2021, trading 10,000 units of IDRA stock currently worth $6,200.
Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
Idera Pharmaceuticals executives and other stock owners filed with the SEC include: